Close monitoring of respiratory function during sleep is essential before initiating GH therapy [23], as it may temporarily increase the risk of OSA in the early weeks of treatment and even worsen SDB in some patients [23]. This evidence concerns the gene GH1 and sleep apnea syndrome.